During the last session, Heron Therapeutics Inc (NASDAQ:HRTX)’s traded shares were 3.87 million, with the beta value of the company hitting 1.36. At the end of the trading day, the stock’s price was $2.40, reflecting an intraday loss of -5.88% or -$0.15. The 52-week high for the HRTX share is $3.93, that puts it down -63.75 from that peak though still a striking 56.67% gain since the share price plummeted to a 52-week low of $1.04. The company’s market capitalization is $365.59M, and the average trade volume was 2.13 million shares over the past three months.
Heron Therapeutics Inc (HRTX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. HRTX has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.01.
Heron Therapeutics Inc (NASDAQ:HRTX) trade information
Heron Therapeutics Inc (HRTX) registered a -5.88% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -5.88% in intraday trading to $2.40, hitting a weekly high. The stock’s 5-day price performance is 40.35%, and it has moved by 42.01% in 30 days. Based on these gigs, the overall price performance for the year is -8.05%.
The consensus price target of analysts on Wall Street is $7, which implies an increase of 65.71% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $5 and $9 respectively. As a result, HRTX is trading at a discount of -275.0% off the target high and -108.33% off the low.
Heron Therapeutics Inc (HRTX) estimates and forecasts
In the rating firms’ projections, revenue will increase 9.62% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 37.08M as predicted by 3 analyst(s). Meanwhile, a consensus of 3 analyst(s) estimates revenue growth to 38.85M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 34.67M and 36.02M respectively. In this case, analysts expect current quarter sales to grow by 6.96% and then jump by 7.84% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 48.68%. While earnings are projected to return 50.00% in 2025.
HRTX Dividends
Heron Therapeutics Inc is due to release its next quarterly earnings in April. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
The next largest institutional holding, with 8.62 million shares, is of VANGUARD GROUP INC’s that is approximately 5.6984% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $30.16 million.
Also, the Mutual Funds coming in first place with the largest holdings of Heron Therapeutics Inc (HRTX) shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF . Data provided on Sep 30, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 4.68 shares. This amounts to just over 3.07 percent of the company’s overall shares, with a $11.24 million market value. The same data shows that the other fund manager holds slightly less at 3.19, or about 2.09% of the stock, which is worth about $7.65 million.
